Ken Griffin’s Trinity Biotech TRIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-1,313
Closed -$38.7K 14089
2025
Q3
$41K Buy
+1,313
New +$41.4K ﹤0.01% 12284
2025
Q2
Sell
-1,385
Closed -$27.8K 15125
2025
Q1
$23.7K Buy
+1,385
New +$32.8K ﹤0.01% 13022
2024
Q4
Sell
-472
Closed -$15.6K 15403
2024
Q3
$15.6K Hold
472
﹤0.01% 12964
2024
Q2
$29.3K Buy
+472
New +$27.5K ﹤0.01% 12300
2024
Q1
Sell
-217
Closed -$13.9K 15446
2023
Q4
$13.9K Buy
+217
New +$15.5K ﹤0.01% 12903
2023
Q3
Sell
-251
Closed -$36.3K 15121
2023
Q2
$36.3K Buy
251
+103
+70% +$15K ﹤0.01% 12151
2023
Q1
$20.9K Buy
+148
New +$22.9K ﹤0.01% 13039
2022
Q1
Sell
-126
Closed -$21.8K 14589
2021
Q4
$27K Buy
126
+8
+7% +$2.27K ﹤0.01% 13511
2021
Q3
$38K Sell
118
-15
-11% -$5.28K ﹤0.01% 13490
2021
Q2
$58K Buy
133
+36
+37% +$18K ﹤0.01% 13273
2021
Q1
$54K Buy
+97
New +$70K ﹤0.01% 12872
2020
Q4
Sell
-349
Closed -$173K 11531
2020
Q3
$105K Buy
349
+282
+421% +$97.9K ﹤0.01% 9247
2020
Q2
$22K Buy
+67
New +$15.3K ﹤0.01% 9535
2017
Q1
Sell
-95
Closed -$99K 8053
2016
Q4
$99K Buy
+95
New +$98.2K ﹤0.01% 6682
2016
Q2
Sell
-88
Closed -$153K 7415
2016
Q1
$153K Buy
+88
New +$140K ﹤0.01% 5817
2015
Q2
Sell
-309
Closed -$892K 9104
2015
Q1
$892K Sell
309
-4
-1% -$11.1K ﹤0.01% 4074
2014
Q4
$823K Buy
313
+65
+26% +$168K ﹤0.01% 4009
2014
Q3
$680K Buy
248
+51
+26% +$166K ﹤0.01% 4206
2014
Q2
$679K Buy
197
+77
+64% +$274K ﹤0.01% 3980
2014
Q1
$436K Buy
120
+58
+94% +$228K ﹤0.01% 4543
2013
Q4
$233K Buy
+62
New +$223K ﹤0.01% 4866

Other funds holding TRIB

Ken Griffin's TRIB Position: Q4 2025 in Review

Ken Griffin sold out of Trinity Biotech (TRIB) in Q4 2025, closing a stake of 1,313 shares — an estimated $38.7K sold.

Ken Griffin first reported a position in TRIB in Q4 2013 and held it in 21 quarters. The position peaked at $892K in Q1 2015. 25 funds tracked by Wall St. Rank hold TRIB as of Q4 2025.

  • Ken Griffin reported no remaining Trinity Biotech position as of Q4 2025 after selling out during the quarter.
  • Ken Griffin sold 1,313 Trinity Biotech shares in Q4 2025, an estimated $38.7K.
  • Ken Griffin first reported a position in Trinity Biotech in Q4 2013 and held it in 21 quarters.
  • Ken Griffin's Trinity Biotech position peaked at $892K in Q1 2015.
  • 25 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.